SecBot SecBot
SECBOTREPLAY Home › Report › BBIO

BBIO · BridgeBio Pharma director Randal Scott filed a Form 144 notice of…

BridgeBio Pharma, Inc. · 144 filed Jun 24, 2026 at 16:34 ET

At the news

NEUTRALIMPACT 2/10

144 filed Jun 24, 2026 at 16:34 ET

BridgeBio Pharma director Randal Scott filed a Form 144 notice of intent to sell 2,196 shares of common stock, with an estimated aggregate market value of approximately $150,711. The shares were acquired via restricted stock units that vested on June 20, 2026. The sale is being conducted under a Rule 10b5-1 trading plan established on June 27, 2025, which mitigates concerns about opportunistic timing. The proposed sale represents a de minimis portion of Scott's holdings relative to the company's $13.6B market cap and is consistent with routine insider diversification.

  • Director Randal Scott filed Form 144 to sell 2,196 shares of BBIO common stock.
  • Estimated aggregate market value of the proposed sale is approximately $150,711.
  • Shares were acquired through restricted stock units that vested on June 20, 2026.
  • Sale is being executed under a Rule 10b5-1 trading plan dated June 27, 2025.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access